Brighter signs a reseller agreement for Actiste® Mini with Medico in Indonesia

Brighter AB (Publ) today announced that it has signed a reseller agreement with Medico – the leading provider of cloud-based healthcare-management systems in Indonesia. Medico also offers a telemedicine app for patients, and wants to be able to offer Actiste® and Actiste® Mini to its patients.

The agreement marks an important step in Brighter’s strategic entry into the Indonesia market. Medico will integrate the Actiste® Mini solution into its e-health portfolio for chronic-disease care and act as a reseller of the device and service. Both companies believe this will differentiate Medico’s offering from the telemedicine services currently available in Indonesia and help Brighter reach the growing group of diabetics in this market. The agreement covers both Actiste® products, but due to the availability of compatible insulin in the Indonesian market the Company currently only sees demand for the Actiste® Mini.

“Many of Medico’s patients have diabetes and we believe they could benefit from features and service provided by Actiste® Mini,” says Erik Lissner, acting CEO of Brighter AB. “We’re very pleased that Medico will integrate our offering into their portfolio and provide Indonesians with an additional tool aiming to support data-driven diabetes care.”

Under the terms of the agreement, Medico will market Actiste® Mini to physicians, pharmacies and consumers. The service will be sold to patients as a 24-month subscription agreement, with an option for renewal at the end of the period. Medico will prepay each subscription it is able to sell and will offer financing options for its patients. 

“Medico is committed to expanding access to healthcare in Indonesia, and we believe that working with Brighter will help more Indonesians become aware of the prevention, risks, and care of diabetes. Diabetes is one of the increasing diseases in Indonesia and is prevalent even among the younger generations, as such working together we hope to nip this problem in the bud,” says Grace Tahir, CEO of Medico.

The reseller agreement is non-exclusive and runs initially for 12 months from the date on which Brighter is able to begin selling the Actiste® in the Indonesian market.  

• Next steps:
  Before sales can commence in the Indonesian market, it will be necessary for Brighter to enter an agreement with an authorised representative who will manage the medical device approval process. The Company is in advanced negotiations with a suitable company. 
• Brighter will carry through the registration process for both medical device and telecommunications approval. Alongside the finalization of the registration process that might take a minimum of three months (the Ministry of Health makes no guarantees on the final process length) Brighter will start the work on pre-launch activities together with Medico.

For further information, please contact:

Investor Relations
IR@brighter.se

Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, 
+46 (0)8 – 684 211 00, adviser@eminova.se, www.eminova.se

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/